Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 24Lung Neoplasms 10Small Cell Lung Carcinoma 5Sarcoma 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Mesothelioma, Malignant 3Head and Neck Neoplasms 3Colorectal Neoplasms 3Colonic Neoplasms 3Breast Neoplasms 3Prostatic Neoplasms 2Pleural Effusion, Malignant 2Ovarian Neoplasms 2Melanoma 2Kidney Neoplasms 2Adenocarcinoma, Bronchiolo-Alveolar 2Adenocarcinoma of Lung 2Uterine Neoplasms 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1STAGE IIIB OR IV NON-SMALL CELL LUNG CANCER 1Pathologic Complete Response 1Parathyroid Neoplasms 1Osteosarcoma 1NSCLC 1Multiple Myeloma 1Mesothelioma 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Pemetrexed 14Carboplatin 13osimertinib 11aflutinib 9Drug Therapy 9Gefitinib 8Radiotherapy 6Docetaxel 6Cisplatin 6pembrolizumab 5anlotinib 5Radiosurgery 5Paclitaxel 5icotinib 4Vinorelbine 4Gemcitabine 4Erlotinib Hydrochloride 4tislelizumab 3camrelizumab 3apatinib 3HM781-36B 3toripalimab 2spartalizumab 2rezivertinib 2dacomitinib 2Tyrosine Kinase Inhibitors 2Thalidomide 2Surgical Procedures, Operative 2S 1 (combination) 2Platinum 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NSCLC × Bortezomib × Thoracic × Clear all
NCT00283634 2011-02-17

A Study of Tarceva for Use in Patients With Relapsed or Refractory Metastatic Non-Small Cell Lung Cancer

Millennium Pharmaceuticals, Inc.

Phase 2 Terminated
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡